At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 30 enrolled
Drug / intervention
Systane Ultra eyedrops +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomised Controlled Trial to Compare the Efficacy of Systane Ultra and Refresh Drop in the Treatment of Dry Eye in Asian Eyes
In Brief
A Phase 3 clinical trial evaluating Systane Ultra eyedrops and Refresh eye drops for Xerophthalmia and Blepharitis. Completed, enrolled 30 participants across 1 site.
Detailed Summary
Systane Ultra is at least as efficacious and safe as Refresh Tears in Asian people with Dry Eyes
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsXerophthalmia, Blepharitis
CountriesSingapore
CollaboratorsAlcon Research
Timeline
Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2008
Enrollment StartJul 2009
Primary CompletionNov 2010
TodayJul 2026
First PostedNov 24, 2008
Enrollment StartJul 1, 2009
Primary CompletionNov 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.6 years ago
Interventions
Systane Ultra eyedropsdrug
Four times a day
Refresh eye dropsdrug
Four times a day